Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS

被引：0

作者：

Bhatt, Surya ^{[1
]}

Rabe, Klaus F. ^{[2
,3
]}

Hanania, Nicola ^{[4
]}

Vogelmeier, Claus F. ^{[5
]}

Bafadhel, Mona ^{[6
]}

Christenson, Stephanie ^{[7
]}

Papi, Alberto ^{[8
]}

Singh, Dave ^{[9
]}

Laws, Elizabeth ^{[10
]}

Akinlade, Bolanle ^{[11
]}

Maloney, Jennifer ^{[11
]}

Lu, Xin ^{[10
]}

Bauer, Deborah ^{[10
]}

Bansal, Ashish ^{[11
]}

Abdulai, Raolat M. ^{[12
]}

Robinson, Lacey B. ^{[12
]}

Bhatt, Surya ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA

[2] LungenClin Grosshansdorf, Grosshansdorf, Germany

[3] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res, Grosshansdorf, Germany

[4] Baylor Coll Med, Dept Med, Sect Pulm & Crit Care Med, Houston, TX USA

[5] Univ Marburg, Dept Med Pulm & Crit Care Med, German Ctr Lung Res, Marburg, Germany

[6] Kings Coll London, Fac Life Sci & Med, Kings Ctr Lung Hlth, Sch Immunol & Microbial Sci, London, England

[7] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA USA

[8] Univ Ferrara, Ferrara, Italy

[9] Manchester Univ NHS Fdn Trust, Univ Manchester, Manchester, England

[10] Sanofi, Bridgewater, NJ USA

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[12] Sanofi, Cambridge, MA USA

来源：

EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷

关键词：

D O I：

10.1183/13993003.congress-2024.PA4787

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[1] Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial
Bhatt, S. P.
Rabe, K. F.
Hanania, N. A.
Vogelmeier, C. F.
Bafadhel, M.
Christenson, S. A.
Papi, A.
Singh, D.
Laws, E.
Akinlade, B.
Maloney, J.
Lu, X.
Bauer, D.
Bansal, A.
Abdulai, R. M.
Robinson, L. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[2] Efficacy and Safety of Dupilumab in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: Pooled Analysis of BOREAS and NOTUS Trials
Robinson, Lacey
Bhatt, Surya
Rabe, Klaus
Hanania, Nicola
Vogelmeier, Claus
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singhphysician, Dave
Laws, Elizabeth
Akinlade, Bolanle
Maloney, Jennifer
Bansal, Ashish
Abdulai, Raolat
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB307 - AB307
[3] Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
Papi, Alberto
Bhatt, Surya P.
Rabe, Klaus F.
Hanania, Nicola A.
Vogelmeier, Claus F.
Bafadhel, Mona
Christenson, Stephanie A.
Singh, Dave
Laws, Elizabeth
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Robinson, Lacey B.
Abdulai, Raolat M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[4] Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial
Bafadhel, M.
Christenson, S. A.
Hanania, N. A.
Bhatt, S. P.
Rabe, K. F.
Vogelmeier, C. F.
Papi, A.
Singh, D.
Laws, E.
Nivens, C.
Bansal, A.
Lu, X.
Bauer, D.
Maloney, J.
Robinson, L. B.
Abdulai, R. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[5] Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial
Rabe, Klaus F.
Vogelmeier, Claus F.
Bhatt, Surya P.
Hanania, Nicola A.
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Robinson, Lacey B.
Abdulai, Raolat M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[6] Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial
Rabe, Klaus F.
Vogelmeier, Claus F.
Bhatt, Surya P.
Hanania, Nicola A.
Bafadhel, Mona
Christenson, Stephanie A.
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Robinson, Lacey B.
Abdulai, Raolat M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[7] DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS
Bhatt, Surya P.
Rabe, Klaus F.
Hanania, Nicola A.
Vogelmeier, Claus
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Dakin, Paula
Maloney, Jennifer
Lu, Xin
Bauer, Deborah
Bansal, Ashish
Abdulai, Raolat
Robinson, Lacey
CHEST, 2024, 166 (04) : 4801A - 4805A
[8] EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
Bhatt, Surya P.
Rabe, Klaus F.
Hanania, Nicola A.
Vogelmeier, Claus F.
Cole, Jeremy
Bafadhel, Mona
Christenson, Stephanie
Papi, Alberto
Singh, Dave
Laws, Elizabeth
Mannent, Leda L. M.
Mortensen, Eric R.
Maloney, Jennifer
Lu, Xin
Bauer, Deborah J.
Bansal, Ashish
Robinson, Lacey
Abdulai, Raolat
CHEST, 2023, 164 (04) : 6531A - 6534A
[9] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
Cork, M. J.
Eichenfield, L. F.
Blauvelt, A.
Rosmarin, D.
Hussain, I.
Davis, J. D.
Li, M.
Zhang, Q.
Gadkari, A.
Eckert, L.
Kamal, M. A.
Bansal, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
[10] Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Zhang, Yihua
Xu, Qiuyun
Chen, Lihong
Chen, Jiawen
Zhang, Jing
Zou, Ying
Gong, Ting
Ji, Chao
FRONTIERS IN IMMUNOLOGY, 2021, 12

← 1 2 3 4 5 →